Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of microbiome deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter microbiome deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 233 microbiome deals announced since 2016 including financial terms where available including links to online deal records of actual microbiome partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of microbiome dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in microbiome dealmaking since 2016.
Chapter 3 provides an overview of the leading microbiome deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in microbiome dealmaking with a brief summary followed by a comprehensive listing of microbiome deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of microbiome deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2016. The chapter is organized by specific microbiome technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in microbiome deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• Browse microbiome collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
• Directory of microbiome deal records covering pharmaceutical and biotechnology
• The leading microbiome deals by value
• Most active microbiome licensing dealmakers
Microbiome Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Fully revised and updated, the report provides details of microbiome deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter microbiome deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 233 microbiome deals announced since 2016 including financial terms where available including links to online deal records of actual microbiome partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of microbiome dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in microbiome dealmaking since 2016.
Chapter 3 provides an overview of the leading microbiome deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in microbiome dealmaking with a brief summary followed by a comprehensive listing of microbiome deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of microbiome deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of microbiome partnering deals signed and announced since Jan 2016. The chapter is organized by specific microbiome technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in microbiome deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Microbiome Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2016• Browse microbiome collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scope
Microbiome Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of microbiome trends and structure of deals entered into by leading biopharma companies worldwide.Microbiome Collaboration and Licensing Deals includes:
• Trends in microbiome dealmaking in the biopharma industry• Directory of microbiome deal records covering pharmaceutical and biotechnology
• The leading microbiome deals by value
• Most active microbiome licensing dealmakers
Microbiome Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
• What are the precise rights granted or optioned?• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Microbiome dealmaking by technology type
Chapter 2 - Trends in microbiome dealmaking
Chapter 3 - Leading microbiome deals
Chapter 4 - Most active microbiome dealmakers
Chapter 5 - Microbiome contracts dealmaking directory
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma
- 9 Meters Biopharma
- Aarhus University
- Abbott Laboratories
- Abbvie
- ADL Bionatur Solutions
- ADM
- AIDS Clinical Trials Group
- Alimentary Health
- Allergan
- ALS Association
- Amag Pharmaceuticals
- American Type Culture Collection (ATCC)
- Ancilia Biosciences
- AnimalBiome
- AntibioTx
- Arc Bio
- Archer Daniels Midland Company
- Arena Pharmaceuticals
- Argonne National Laboratory
- Ariana Pharma
- Arranta Bio
- Artizan Biosciences
- Assembly Biosciences
- AstraZeneca
- Aurealis Therapeutics
- Azitra
- BASF
- Bayer
- Bayer CropScience
- Bayer Healthcare
- Baylor College of Medicine
- Baylor Miraca Genetics Laboratories
- Beam Therapeutics
- Bertin Pharma
- Bill and Melinda Gates Foundation
- Bio-Me
- Bio-Rad Laboratories
- BIOASTER
- Biocodex Microbiota Foundation
- Biocogent
- Biocore
- Biofortis
- Biohaven Pharmaceuticals
- BiomeBank
- Biomecite Diagnostics
- Biomedical Advanced Research and Development Authority
- Biomica
- Biomillenia
- Biomodels
- BiomX
- BionX Medical Technologies
- Bio Palette
- Biosortia Pharmaceuticals
- Bloom Science
- Boehringer Ingelheim
- Boston University School of Medicine
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Brown University
- Cancer Research UK
- CARB-X
- Carbiotix
- Cargill
- Cedars-Sinai Medical Center
- Centers for Disease Control and Prevention
- Centre Leon Berard
- Centre National de la Recherche Scientifique
- Centro Sperimentale del Latte
- Children's Hospital Boston
- Circuit Clinical
- Clalit Health Services
- CN Bio
- Commense
- Companion PBx
- Compass Minerals Plant Nutrition
- ConsortiaTX
- COPD Foundation
- CoreBiome
- Cornell University
- CosmosID
- Crohn's and Colitis Foundation of America
- CryoXtract
- Dana-Farber Cancer Institute
- DayTwo
- DDL Diagnostic Laboratory
- Debiopharm
- Defense Advanced Research Projects Agency
- Department of Health and Human Services
- Dermala
- Diversigen
- DuPont
- DuPont Pharmaceuticals
- DuPont Pioneer
- Eagle Genomics
- EcoMetrix
- Elanco
- Eligo Bioscience
- Emulate
- EnBiotix
- Enterome Bioscience
- EpiBiome
- European Commission
- Evah
- Evelo Biosciences
- Evogene
- Evolve BioSystems
- Evotec
- ExeGi Pharma
- Felix Biotechnology
- Ferring Pharmaceuticals
- Finch Therapeutics
- Florida International University
- Food Marble Digestive Health
- Forsyth Institute
- French National Institute for Agricultural Research
- Fundacion Progreso y Salud
- Galmed Pharmaceuticals
- Genentech
- General Automation Lab Technologies
- Genetic Analysis
- Genewiz
- Genome and Company
- GenomeQuest
- Georges Francois Leclerc Center
- German Cryo
- Gilead Sciences
- Ginkgo BioWorks
- GlaxoSmithKline
- Glycosyn
- Gnubiotics Sciences
- Greenteaspoon
- Hackensack Meridian Health
- Hadassah Medical Center
- Hamilton Company
- Harvard School of Public Health
- Harvard T.H. Chan School of Public Health
- Harvard University
- Helomics
- HLH BioPharma Vertriebs
- Holobiome
- Horizon 2020
- Hospital of University of Strasbourg
- Hudson Institute of Medical Research
- Human Longevity
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
